Niki BioSolutions, Inc. (NIKI) · Oct 13, 2026 · Exec change

Niki BioSolutions CFO appointment flags funding dependence

CFO appointment — $250,000 base salary; $25,000 deferred until $3M funding

Niki BioSolutions appoints Thomas Freeburg as CFO, adding finance experience but tying compensation to future capital raises.

Niki BioSolutions is a recently reorganized, clinical-stage life-sciences company building genomic and biomarker testing capabilities around brain health, oncology, and an Alzheimer’s program after its 2026 merger with DiamiR. The filing completes the post-merger executive buildout with an experienced CFO. Thomas Freeburg brings prior CFO, chief accounting officer, SEC-reporting, and public-company finance experience, and the agreement gives him responsibility for the company’s day-to-day financial operations and financial strategy. 〔0〕 〔1〕 The buried signal is that financing remains central to the operating plan. His $250,000 base salary includes $25,000 deferred until the company receives cumulative capital investment of $3 million, while the salary rises to $275,000 after $5 million of funding. That makes the appointment less a sign of a fully funded platform than a sign the company is still structuring itself around the next raise. 〔2〕 The compensation package is meaningful for an early-stage company but not an obvious strategic reset. Freeburg is eligible for a bonus of up to 50% of base salary and receives 50,000 options at an $8.83 exercise price, adding future dilution potential while aligning part of his compensation with equity value creation. 〔3〕 Bottom line: This is a constructive governance upgrade, but the funding-linked pay terms make the bigger takeaway capital dependence rather than business progress. The direction was already visible from the recent post-merger management buildout, so the filing matters modestly.

Original filing on SEC EDGAR

More Niki BioSolutions, Inc. news

Niki BioSolutions CFO appointment flags funding dependence | NIKI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.